Pharmacokinetic/Pharmacodynamic Modeling of the Antinociceptive Effects of (+)-Tramadol in the Rat: Role of Cytochrome P450 2D Activity
Authors:
- Marı́a J. GarridoMGMarı́a J. Garrido
- Marı́a Carmen Dios-ViéitezMDMarı́a Carmen Dios-Viéitez
- Marı́a Jesús RenedoMRMarı́a Jesús Renedo
- Iñaki F. TrocónizIñaki F. Trocóniz
Open Access
- 1 May 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 305 (2) , 710-718
Abstract
In this study the role of cytochrome P450 2D (CYP2D) in the pharmacokinetic/pharmacodynamic relationship of (+)-tramadol [(+)-T] has been explored in rats. Male Wistar rats were infused with (+)-T in the absence of and during pretreatment with a reversible CYP2D inhibitor quinine (Q), determining plasma concentrations of Q, (+)-T, and (+)-O-demethyltramadol [(+)-M1], and measuring antinociception. Pharmacokinetics of (+)-M1, but not (+)-T, was affected by Q pretreatment: early after the start of (+)-T infusion, levels of (+)-M1 were significantly lower (P < 0.05). However, at later times during Q infusion those levels increased continuously, exceeding the values found in animals that did not receive the inhibitor. These results suggest that CYP2D is involved in the formation and elimination of (+)-M1. In fact, results from another experiment where (+)-M1 was given in the presence and in absence of Q showed that (+)-M1 elimination clearance (CLME0) was significantly lower (P < 0.05) in animals receiving Q. Inhibition of both (+)-M1 formation clearance (CLM10) and CLME0 were modeled by an inhibitoryEMAX model, and the estimates (relative standard error) of the maximum degree of inhibition (EMAX) and IC50, plasma concentration of Q eliciting half of EMAXfor CLM10 and CLME0, were 0.94 (0.04), 97 (0.51) ng/ml, and 48 (0.42) ng/ml, respectively. The modeling of the time course of antinociception showed that the contribution of (+)-T was negligible and (+)-M1 was responsible for the observed effects, which depend linearly on (+)-M1 effect site concentrations. Therefore, the CYP2D activity is a major determinant of the antinociception elicited after (+)-T administration.Keywords
This publication has 23 references indexed in Scilit:
- Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity1999
- Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: Application to pharmacokinetic studiesChirality, 1999
- Interchangeability and Predictive Performance of Empirical Tolerance ModelsClinical Pharmacokinetics, 1999
- Polymorphic CYP2D6 mediates O -demethylation of the opioid analgesic tramadolEuropean Journal of Clinical Pharmacology, 1997
- The hypoalgesic effect of tramadol in relation to CYP2D6*Clinical Pharmacology & Therapeutics, 1996
- Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cellsEuropean Journal of Pharmacology, 1996
- The metabolism of tramadol by human liver microsomesJournal of Molecular Medicine, 1992
- Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoinClinical Pharmacology & Therapeutics, 1992
- The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in manBiochemical Pharmacology, 1989
- Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strainsJournal of Pharmacy and Pharmacology, 1981